To recover your password please fill in your email address
Please fill in below form to create an account with us
MOST 18 SUBSTUDY 41 - 42: Sotorasib
A Single arm, open label, signal-seeking phase II study of Sotorasib (AMG-510) in patients with solid tumours harbouring KRAS G12C mutation.
|
Trial Summary: |
The aim of this MoST substudy is to assess the clinical activity of Sotorasib in adult patients with advanced cancers (excluding NSCLC and colorectal cancers) harbouring KRAS G12C mutations. |
|
Supported By: |
|
|
Eligibility: |
Adults patients with treatment-refractory solid tumours (except non-small-cell lung and colorectal cancers) harbouring KRAS G12C mutation as determined by next generation sequencing panel. |
|
Registration ID: |
ACTRN12621001690842 |
|
Participation: |
National |
|
Status: |
Recruiting |
|
Activation Date: |
07/07/2022 |
|
Chairs: |
Prof Jayesh Desai Dr Frank Lin |
|
Contact: |